New drug cocktail shows promise for tough prostate cancer

NCT ID NCT03934840

Completed Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested a combination of three drugs—carboplatin, cabazitaxel, and abiraterone—in 61 men with high-volume metastatic prostate cancer that still responds to hormone therapy. The goal was to see how many men had no cancer growth after one year. The study also tracked side effects and how long the cancer stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carboplatin, cabazitaxel, abiraterone, and prednisone
What this could lead to: If successful, this combination could offer a new treatment option to delay cancer progression in men with advanced prostate cancer.
What could go wrong: This is a small, early-phase trial with only 61 participants. The combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169, United States
Lifespan Cancer Institute

Providence, Rhode Island, 02903, United States
Masonic Cancer Center at University of Minnesota

Minneapolis, Minnesota, 55455, United States
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Northwestern University

Chicago, Illinois, 60611, United States
Thomas Jeferson University

Philadelphia, Pennsylvania, 19107, United States
Tulane University

New Orleans, Louisiana, 70112, United States
University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.